Semaglutide

Looking for an effective weight loss solution? Semaglutide might be the perfect option for you. We offer Semaglutide of the highest quality and at the best price. Our trained team is always available to provide support and answer any questions you may have. Take control of your weight today!

Proven Medication

Custom Formulation

Semaglutide is the active ingredient in Ozempic® and Wegovy® It is a reliable treatment option for those looking for a boost to their weight loss efforts. Our compounded injectable semaglutide is the highest quality and comes at the best price.

Consult with a physician now or speak with your doctor about semaglutide and how it can help you on your weight loss journey! Obtaining this effective medication has never been easier.

*Photos of models, not actual patients

*Semaglutide is a compounded product and has not been approved by the FDA

How to get started

Select the compounded medication that treats your ailment.

1.

Consult with a licensed physician via XpediCare ($39) now or talk to your doctor

2.

3.

We will prepare your medication specifically for you

4.

You'll be notified that your treatment is ready or we can ship to your door!

Pricing

$119

1mg vial

For individuals on the 0.25mg dose

$180

5mg vial

For individuals on the 0.5mg or 1mg dose

$249

12.5mg vial

For individuals on the 1.7mg dose or higher

Start Consultation

For Your Doctor

5mg/2ml Semaglutide injection #2ml

Inject subcutaneously as directed once weekly

bradleyjhart

Compounded Semaglutide Now Available!

We are thrilled to introduce the latest addition to our medication offerings: compounded injectable semaglutide. Our compounded...

What is this drug used for?

Ozempic prefilled pens and Rybelsus tablets:

• It is used to lower blood sugar in patients with type 2 diabetes.

Ozempic prefilled pens:

• It is used to lower the chance of heart attack, stroke, and death in people with type 2 diabetes and heart disease.

Wegovy prefilled pens:

• It is used to help with weight loss in certain people.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

If using for high blood sugar:

• Constipation, diarrhea, stomach pain, upset stomach, or throwing up

Tablets:

• Decreased appetite

If using for weight loss:

• Constipation, diarrhea, stomach pain, upset stomach, or throwing up

• Headache

• Feeling dizzy, tired, or weak

• Nose or throat irritation

• Runny nose

• Bloating

• Burping

• Gas

• Heartburn

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

For all uses of this drug:

• Neck mass, trouble breathing, trouble swallowing, or have hoarseness that will not go away

• Kidney problems like unable to pass urine, change in how much urine is passed, blood in the urine, or a big weight gain

• Gallbladder problems like pain in the upper right belly area, right shoulder area, or between the shoulder blades; change in stools; dark urine or yellow skin or eyes; or fever with chills

• Severe dizziness or passing out

• A fast heartbeat

• Change in eyesight

• Low blood sugar like dizziness, headache, feeling sleepy or weak, shaking, fast heartbeat, confusion, hunger, or sweating

• Pancreas problems (pancreatitis) like severe stomach pain, severe back pain, or severe upset stomach or throwing up

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

If using for weight loss:

• New or worse behavior or mood changes like depression or thoughts of suicide

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

FDA approval date

December 05, 2017

Generic name

Semaglutide

Mechanism of action

Semaglutide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist that increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying; also acts in the areas of the brain involved in regulation of appetite and caloric intake.

Distribution

Vd: Oral: ~8 L; SUBQ: ~12.5 L.

Metabolism

Proteolytic cleavage of the peptide backbone with sequential beta-oxidation of the fatty acid sidechain.

Excretion

Urine (~3% as unchanged drug), feces.

Time to peak

Plasma: Oral: 1 hour; SUBQ: 1 to 3 days.

Half-life elimination

~1 week.

Protein binding

>99% to albumin.

Bioavailability

Oral: ~0.4% to 1%; SUBQ: 89%.

Dosage: Adult

Clinical considerations: May require a dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia.(Ref)

FDA-approved uses

Diabetes mellitus, type 2, treatment (Ozempic)

Note: May be used as an adjunctive agent or alternative monotherapy for patients who fail initial therapy with lifestyle intervention and metformin or who cannot take metformin. May be preferred in patients who have or are at risk for atherosclerotic cardiovascular disease, when weight loss is desired, and/or in patients with an HbA1c relatively far from goal (eg, HbA1c 9% to 10%) and type 1 diabetes is not likely.(Ref) Consider slower dose titration in patients with diabetic retinopathy to avoid exacerbating the condition.(Ref) Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor.(Ref)

Initial dosage

0.25 mg SUBQ once weekly for 4 weeks. Note: The lower initial dose (0.25 mg weekly) is intended to reduce GI symptoms; it does not provide effective glycemic control.(Ref) If changing the day of administration is necessary, allow at least 48 hours between 2 doses.(Ref)

Dosage titration

After 4 weeks on the 0.25 mg/week dose, increase to 0.5 mg SUBQ once weekly. May increase to 1 mg once weekly after 4 weeks on the 0.5 mg/week dose if needed to achieve glycemic goals; may increase further to 2 mg once weekly after 4 weeks on the 1 mg/week dose if needed to achieve glycemic goals.(Ref)

Conversion

From oral semaglutide to Ozempic

If current oral dose is 7 mg once daily

There is no equivalent SUBQ dose provided in the manufacturer's labeling; some experts convert to 0.5 mg SUBQ once weekly, beginning the day after the last oral dose; monitor glucose more closely during transition.(Ref)

If current oral dose is 14 mg once daily

Convert to 0.5 mg SUBQ once weekly, beginning the day after the last oral dose.(Ref)

From Ozempic to oral semaglutide

If current SUBQ dose is 0.5 mg once weekly

Convert to 7 or 14 mg orally once daily, beginning within 7 days of the last injection.(Ref)

If current SUBQ dose is 1 mg once weekly

There is no equivalent oral dose provided in the manufacturer's labeling; some experts convert to 14 mg orally once daily, beginning within 7 days of the last injection.(Ref)

Weight management, chronic (Wegovy)

Note: For use as an adjunct to diet and exercise in patients with a BMI ≥30 kg/m2, or in patients with a BMI ≥27 kg/m2 and ≥1 weight-associated comorbidity (eg, hypertension, dyslipidemia); may be preferred in patients with established cardiovascular disease.(Ref)

Initial dosage

0.25 mg SUBQ once weekly.(Ref)

Dosage titration

Adjust dosage using the following schedule: In patients who do not tolerate a dosage increase, consider delaying the increase for an additional 4 weeks:

Week 1 through week 4

0.25 mg SUBQ once weekly.(Ref)

Week 5 through week 8

0.5 mg SUBQ once weekly.(Ref)

Week 9 through week 12

1 mg SUBQ once weekly.(Ref)

Week 13 through week 16

1.7 mg SUBQ once weekly.(Ref)

Week 17 and thereafter (maintenance dosage)

2.4 mg SUBQ once weekly (preferred regimen); if not tolerated, may use an alternative maintenance dosage of 1.7 mg SUBQ once weekly.(Ref)

Discontinuation of therapy

The manufacturer recommends discontinuing therapy in patients who cannot tolerate the 1.7 mg/week dosage; however, some patients may achieve goal weight loss on a submaximal dose and may continue on the maximum tolerated dose (even if <1.7 mg/week).(Ref) Consider discontinuation if at least 5% of baseline body weight loss has not been achieved within 3 months.(Ref)

Forest Park Pharmacy

2410 Forest Park Blvd.
Fort Worth, TX 76110

(682) 250-3116

Semaglutide